Blog - Page 3000 of 5694

WednesdayJun 26, 2013 11:25 am

ISC8, Inc. (ISCI) Signs Agreement with a Leading UK Mobile Operator

ISC8, a provider of intelligent cyber security solutions, announced today the entrance into a one-year support agreement with a prominent UK mobile operator's product, Cyber NetControl™. Under framework services, support, and license agreement, ISC8 Secure® has been recruited to supply, install, implement, maintain, and support the Cyber NetControl System, which will provide content filtering for millions of subscribers. A high performance, carrier-grade platform, Cyber NetControl allows service providers and enterprises alike to protect users from accessing inappropriate content on a network-wide or per-user basis. The platform combines web filtering and traffic enforcement for comprehensive as well as accurate policy enforcement.…

WednesdayJun 26, 2013 11:03 am

5BARz International Inc. (BARZ) Patented Technology for Cell Phone Signal Boosters Meet and Exceed Requirements Set by the FCC

On February 20, 2013, the FCC issued a Report & Order on Signal Boosters which includes rules, policies and specific technical features to protect against interference that may harm the operator’s network. The FCC stated in that report, “We find that these technical safeguards are vital to the development of signal boosters that significantly expand coverage for consumers and do not harm wireless networks. The record reflects that some existing boosters, particularly those that do not provide built-in safeguards, have caused substantial interference to both commercial and public safety.” The CEO of 5Barz International Inc., Mr. Daniel Bland, explained that…

WednesdayJun 26, 2013 11:00 am

Premier Biomedical, Inc. (BIEL) Posts Favorable Phase 1 Clinical Trial for Breast Cancer Treatment

Premier Biomedical has released the results of a completed phase 1 mouse testing of its breast cancer therapy, with results demonstrating the methodology’s ability to outperform chemotherapy with a much lower mortality rate, smaller tumor volume, and increased subject weight gain recorded 19 days after first treatment. Twenty-five days into the study, the mice administered Premier Biomedical's treatment experienced a 100 percent survival rate without encountering a single cancer-related fatality. This is compared to a mortality rate of nearly one-third of the mice subjected to chemotherapy. In addition, the tumors of the mice given Premier Biomedical's treatment shrunk in size…

WednesdayJun 26, 2013 10:08 am

Frozen Food Gift Group, Inc. (FROZ) Serves Diverse and Growing Client Base

Frozen Food Gift Group, through the company’s wholly owned subsidiary, Miami Ice Machine Company (MIMCO), is a leading provider of ice machines and refrigeration equipment, serving a variety of industries primarily in Florida, plus exporting to the Caribbean, Central and South America. As machine manufacturers, MIMCO has developed a full lineup of ice machines for business, no matter what the application, including the following: • Supermarkets • Convenience Stores • Health Care Centers • Cruise Ships • Restaurants • Bars & Night Clubs • Maritime Vessels • Special Events MIMCO has manufactured and installed more than 100,000 pieces of equipment…

WednesdayJun 26, 2013 8:36 am

BIO-key International, Inc. (BKYI) TruDonor Fingerprint Identification System Implemented by Suncoast Communities Blood Bank

BIO-key International has announced that Suncoast Communities Blood Bank (SCBB) has successfully launched the company’s TruDonor donor search and identification solution, providing the security and convenience of automated positive donor identification at all SCBB donor centers. SCBB received a grant from the Venice Endowment Fund through the Gulf Coast Community Foundation in support of purchasing the new fingerprint donor identification system. The new donor identification system from BIO-key will allow SCBB to more efficiently search for and positively identify blood donors, at the same time enabling the detection and prevention of duplicate donor records, the protection of donor privacy, and…

TuesdayJun 25, 2013 12:08 pm

Cardium Therapeutics, Inc. (CXM) Positioned to Advance Leading Products with Experienced Leadership at the Helm

Cardium Therapeutics has established a diversified portfolio of medical products with large market potential. Armed with a capital-efficient, asset-based business strategy, the company is positioned to continue to build its portfolio with balanced risk/return opportunities in a variety of markets and is working to secure approval for marketing and sale in South Korea and the European Union. Company CEO Christopher J. Reinhard founded the company in December 2003, backed by nearly 15 years of focus on the commercial development of cardiovascular growth factor therapeutics. Under Reinhard’s leadership, Cardium is working to advance its ASPIRE Generx® clinical study at major medical…

TuesdayJun 25, 2013 11:04 am

5BARz International, Inc. (BARZ) Appoints Behrooz Lessani as the Company’s Vice President of Business Development

5BARz International, in establishing it's position as a leader in providing wireless coverage solutions using network extender devices, has today announced the appointment of the new Vice President of Business Development, to lead 5Barz's European hub, based in the UK to establish a full-scale operation including sales, marketing and support. As the 5BArz technology gains increasing interest from wireless network operators, establishing infrastructure to service the needs of Telecom operators headquartered in Europe is an important milestone for 5Barz. Behrooz Lessani, a Telecom Executive, has extensive business development experience in the industry. Behrooz was recently at InterDigital Communications, where he…

TuesdayJun 25, 2013 11:04 am

5BARz International, Inc. (BARZ) Appoints Behrooz Lessani as the Company's Vice President of Business Development

TuesdayJun 25, 2013 11:03 am

DoMark International, Inc. (DOMK) Successfully Targets Critical Mobile Charging Market

DoMark International seeks out companies offering profitable technologies with proven markets. It’s a term that perfectly describes the company’s primary subsidiary, SolaWerks, serving one of the modern world’s most widespread and expanding markets, mobile devices. SolaWerks sells their own proprietary and superior technology for charging some of the most popular mobile devices. Their systems incorporate a unique system for capturing invisible infrared radiation, allowing Apple and Samsung devices to be charged both indoors and outdoors. Anyone who questions the importance of mobile device charging need only reflect on events immediately following Superstorm Sandy. For days after the storm, restaurants all…

TuesdayJun 25, 2013 8:54 am

Anthera Pharmaceuticals, Inc. (ANTH) Initiates BRIGHT-SC Phase 2 Clinical Study of Blisibimod for Treating IgA Nephropathy

Biopharmaceutical company Anthera Pharmaceuticals has announced the initiation of the BRIGHT-SC Phase 2 study of blisibimod, which is a novel inhibitor of B-cell activating factor (BAFF) for treating IgA nephropathy. A chronic autoimmune renal disease, IgA nephropathy is characterized by proteinuria and progression to end-stage renal disease. A multicenter, placebo-controlled, double-blind Phase 2 clinical study, the BRIGHT-SC trial is anticipated to enroll a minimum of 48 patients from Asia Pacific geographies, who will then be randomized into one active treatment arm or one placebo arm. The study’s primary endpoint will be a reduction in proteinuria at 32 weeks. After the…

Site Search

Company Search